Atorvastatin 20mg + Clopidogrel 75mg + Aspirin 75mg

Product Introduction

Atorvastatin 20mg + Clopidogrel 75mg + Aspirin 75mg combines atorvastatin, clopidogrel, and aspirin for selected high-risk cardiovascular patients. It is typically used when cholesterol lowering plus dual antiplatelet therapy is prescribed, such as after certain acute coronary syndromes, coronary stent placement, or other specialist-directed situations. Atorvastatin reduces LDL cholesterol and supports plaque stabilization. Aspirin and clopidogrel reduce platelet clumping through different pathways, lowering the chance of arterial clot formation. Because two antiplatelet medicines are included, bleeding risk is higher than with a statin alone or a single antiplatelet. Patients should know the bleeding warning signs, avoid duplicate aspirin/NSAIDs unless directed, and tell all clinicians before surgery, dental work, or procedures.

How to use

Take Atorvastatin 20mg + Clopidogrel 75mg + Aspirin 75mg exactly as prescribed, commonly after food to reduce stomach upset. Do not skip doses or stop suddenly without the prescriber's advice, especially after stent placement. Avoid extra aspirin, NSAIDs, anticoagulants, or herbal blood-thinning products unless reviewed.

How it works

Atorvastatin lowers LDL by inhibiting HMG-CoA reductase. Aspirin reduces thromboxane-mediated platelet activation. Clopidogrel blocks platelet P2Y12 receptors after metabolic activation. Together they address plaque biology and clot formation.

Common side effects

Possible effects include acidity, stomach pain, diarrhoea, bruising, nosebleeds, headache, rash, muscle aches, and abnormal liver tests. Serious warning signs include black stools, vomiting blood, heavy or persistent bleeding, severe stomach pain, stroke-like symptoms, severe allergic reaction, jaundice, dark urine, or severe muscle weakness.

Important information

Use only under specialist or prescriber direction. Avoid in active bleeding, recent bleeding stroke, severe liver disease, aspirin allergy, uncontrolled ulcer disease, or high bleeding risk unless benefits clearly outweigh risks. CYP2C19 poor-metabolizer status and omeprazole/esomeprazole use may reduce clopidogrel effect.